# Identity Testing for Protein Therapeutics

## Quick Answer

- Peptide mapping and intact mass analysis confirm protein identity by matching observed mass and fragment patterns to the predicted sequence.
- Start with intact protein mass measurement to detect sequence variants, then use peptide mapping to localize any differences.
- Identity testing confirms what the protein is, not whether it is pure, potent, or correctly folded, so pair it with orthogonal assays.

## At a Glance

| Method | What It Confirms | Key Data Output | Primary Limitation |
| --- | --- | --- | --- |
| Intact mass analysis | Whole-protein molecular weight | Average or deconvoluted mass spectrum | Cannot localize modifications to specific residues |
| Peptide mapping | Sequence coverage and modification sites | Peptide mass list and fragment spectra | Requires complete digestion and high-quality separation |
| Tandem mass spectrometry | Amino acid sequence confirmation | Fragment ion series | Data interpretation requires specialized software |
| Edman degradation | N-terminal sequence confirmation | Sequential amino acid assignments | Limited to short sequences and blocked N-termini |

## Why Protein Identity Testing Matters

Protein identity testing answers a foundational question in biopharmaceutical development and quality control: is the protein product what it is claimed to be? This question is distinct from purity, potency, or activity. A preparation can be pure and active yet contain the wrong protein, a truncated variant, or a sequence error introduced during cloning or expression. Identity testing establishes the molecular correspondence between the product and its intended sequence.

The stakes are high in regulated environments. Release testing for biopharmaceutical products requires evidence that each batch matches the reference standard. Identity testing also supports process development, where expression systems can introduce unintended sequence changes. For research laboratories, identity confirmation prevents downstream experiments from being built on a misidentified protein.

The core analytical tools for identity testing are mass spectrometry and peptide mapping. These methods compare the measured properties of the protein against a predicted profile derived from the DNA sequence. The comparison is only as reliable as the reference sequence and the quality of the analytical measurement. NIST laboratory programs emphasize that measurement science depends on standards, calibration, and documented quality practices. The same principle applies to protein identity testing: the reference materials and instrument calibration determine the confidence in the result.

## Core Principles of Protein Identity Testing

### The Relationship Between Sequence and Mass

Every protein has a predictable molecular mass based on its amino acid sequence. The average mass accounts for the natural isotopic distribution of carbon, hydrogen, nitrogen, oxygen, and sulfur. The monoisotopic mass uses the most abundant isotope of each element. For proteins larger than a few kilodaltons, the isotopic envelope becomes broad, and the average mass is the practical measurement target.

The measured mass of an intact protein is compared with the mass calculated from the predicted sequence. A match within the instrument's mass accuracy confirms that the protein has the expected length and amino acid composition. A mass difference indicates a sequence variant, a post-translational modification, or a processing artifact. The mass difference itself provides a clue: a loss of 18 daltons suggests dehydration, a gain of 80 daltons suggests phosphorylation, and a shift of 16 daltons suggests oxidation.

Intact mass analysis is fast and requires minimal sample preparation. It is the first-line identity check because it can detect gross errors such as truncation, fusion, or incorrect expression. The limitation is that the intact mass is a single number. Two different modifications at different sites can produce the same total mass shift. Localizing the modification requires peptide mapping.

### Peptide Mapping as a Sequence Fingerprint

Peptide mapping digests the protein into peptides using a sequence-specific protease, separates the peptides by liquid chromatography, and detects them by mass spectrometry. The resulting peptide map is a fingerprint of the protein sequence. Each peptide has a predicted mass based on the digestion pattern of the known sequence. The observed peptide masses are matched against the predicted list.

A complete peptide map covers the entire sequence. Gaps in coverage mean that some regions of the protein were not observed, and those regions remain unverified. The digestion must be reproducible so that the peptide map is consistent between runs. The separation must resolve peptides that differ by small mass changes, such as a deamidation event that adds one dalton.

Tandem mass spectrometry adds a second stage of analysis. A selected peptide is fragmented in the mass spectrometer, and the fragment masses are used to derive the amino acid sequence of that peptide. This approach confirms the sequence at the residue level and can localize a modification to a specific amino acid. The fragment spectra are compared with predicted spectra or searched against a protein database.

The quality of the peptide map depends on the completeness of digestion. Incomplete digestion produces missed cleavages that complicate the peptide list. Overdigestion can produce nonspecific cleavages that are difficult to assign. The choice of protease, digestion time, and temperature must be optimized for each protein.

## Analytical Workflow for Identity Confirmation

### Step 1: Establish the Reference Sequence

The reference sequence is the standard against which all measurements are compared. It is derived from the DNA sequence used to express the protein. The reference must include the signal peptide if present, the mature sequence, and any expected post-translational processing. The reference sequence is the basis for calculating the expected intact mass and the expected peptide masses.

The reference sequence must be verified independently. A sequence error in the reference will produce a systematic mismatch between observed and expected data. The reference should be checked against the original cloning records and, if possible, confirmed by DNA sequencing of the expression construct. The NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules provide the oversight context for work with recombinant constructs, and the laboratory should document the sequence verification steps.

The reference sequence is stored in a format that can be used by the analysis software. The software calculates the theoretical mass of the intact protein and the theoretical masses of the digestion peptides. The reference sequence is the anchor of the entire identity testing workflow.

### Step 2. Intact Mass Analysis

Intact mass analysis is the first measurement in the workflow. The protein is analyzed by mass spectrometry without digestion. The instrument measures the mass-to-charge ratio of the protein ions, and the data are deconvoluted to produce the neutral mass.

The measured mass is compared with the predicted mass. The acceptable mass difference depends on the instrument and the protein size. A high-resolution instrument can achieve mass accuracy in the low parts per million range for proteins up to several tens of kilodaltons. The mass difference is reported as the mass error.

A mass error within the expected range supports the identity of the protein. A mass error outside the expected range requires investigation. The mass difference is the first clue to the nature of the discrepancy. A mass shift that matches a known modification, such as the addition of a phosphate group, suggests a specific modification. A mass shift that does not match any known modification requires further analysis.

Intact mass analysis does not localize the modification. The mass shift is the sum of all modifications across the protein. Two modifications at different sites can produce the same total mass shift. The intact mass analysis is therefore a screening step, and the localization is performed by peptide mapping.

### Step 3. Proteolytic Digestion

The protein is digested into peptides using a sequence-specific protease. The most common choice is trypsin, which cleaves at the C-terminal side of lysine and arginine residues. Other proteases such as chymotrypsin, LysC, and AspN can be used to generate overlapping peptides or to cover regions that are not accessible to trypsin.

The digestion conditions are optimized for each protein. The protein is denatured to expose the cleavage sites. A reducing agent breaks disulfide bonds, and an alkylating agent prevents the disulfide bonds from reforming. The digestion time and temperature are controlled to achieve complete digestion without producing nonspecific cleavages.

The digestion is a critical step for reproducibility. The peptide map must be consistent between runs so that the identity comparison is meaningful. The digestion protocol must be documented and followed exactly. The quality of the digestion is assessed by the peptide coverage and the absence of missed cleavages.

### Step 4. Liquid Chromatography and Mass Spectrometry

The peptide mixture is separated by liquid chromatography before mass spectrometry. The separation reduces the complexity of the mixture and allows the mass spectrometer to analyze each peptide individually. The chromatography is typically reversed-phase, with a gradient of organic solvent.

The mass spectrometer detects the peptides as they elute from the column. The instrument records the mass-to-charge ratio of each peptide and, in tandem mode, fragments the peptides to produce sequence information. The data are collected as a function of retention time and mass.

The quality of the chromatography affects the quality of the peptide map. The separation must be reproducible so that the retention times are consistent between runs. The mass spectrometer must be calibrated so that the mass measurements are accurate. The calibration is performed with a known standard, and the calibration is verified before each run.

### Step 5. Data Analysis and Sequence Coverage

The mass spectrometry data are processed to produce a list of peptide masses and, in tandem mode, peptide sequences. The observed peptides are matched against the theoretical peptides derived from the reference sequence. The match is based on the mass and, when available, the fragment spectrum.

The sequence coverage is the percentage of the protein sequence that is confirmed by the observed peptides. A high sequence coverage is required for a confident identity assignment. The coverage is calculated by dividing the number of amino acids covered by the total number of amino acids in the sequence.

The interpretation of the data requires a threshold for acceptance. The threshold is based on the mass accuracy of the instrument and the quality of the fragment spectra. The threshold is documented in the analysis method and is applied consistently to all samples.

The interpretation must account for the limitations of the method. A peptide that is not observed does not prove that the sequence is absent. The peptide may be too small or too large to be detected, or it may be modified in a way that changes its mass. The absence of a peptide is a gap in coverage, and the gap must be addressed by additional analysis.

## Instrumentation and Method Selection

### Mass Spectrometry Platforms

The mass spectrometer is the core instrument for protein identity testing. The choice of platform depends on the required mass accuracy, the resolution, and the fragmentation capabilities. The most common platforms are quadrupole time-of-flight, Orbitrap, and triple quadrupole instruments.

The quadrupole time-of-flight instrument provides high mass accuracy and resolution. It is suitable for intact mass analysis and peptide mapping. The Orbitrap provides high resolution and mass accuracy and is well suited for the analysis of complex peptide mixtures. The triple quadrupole is used for targeted analysis, where the instrument is set to detect specific peptides.

The mass accuracy of the instrument is a key parameter. The mass accuracy is the difference between the measured and the true mass, expressed in parts per million. A mass accuracy of 10 ppm or better is typical for modern instruments. The mass accuracy is verified by calibration with a standard.

The resolution of the instrument determines the ability to distinguish between two masses that are close together. The resolution is the ability to separate two peaks of similar mass. A high resolution is required to detect modifications that produce a small mass shift.

### Separation and Digestion Reagents

The quality of the separation and digestion reagents affects the quality of the data. The protease must be sequence-specific and free of contaminating activities. The digestion buffer must be compatible with the protease and the protein. The chromatography column must be reproducible and stable.

The reagents are a source of variability in the analysis. The digestion efficiency can vary between lots of the protease. The chromatography column can vary between batches. The variability is controlled by using a reference standard and by monitoring the performance of the system.

The reference standard is a protein of known sequence and mass. The standard is analyzed at the beginning of each run to verify the performance of the instrument. The standard is also used to calibrate the mass accuracy and to monitor the reproducibility of the separation.

### Data Analysis Software

The data analysis software is used to process the mass spectrometry data and to match the observed peptides against the reference sequence. The software is a critical component of the workflow. The software must be able to handle the data format from the instrument and to perform the database search.

The software is used to calculate the theoretical masses of the peptides and to match the observed masses. The software is also used to interpret the fragment spectra and to assign the peptide sequences. The software is used to calculate the sequence coverage and to report the results.

The software must be validated for its intended use. The validation includes testing the software with known data and verifying that the results are correct. The validation is documented and is part of the quality system.

## Controls and Quality Assurance

### Positive and Negative Controls

The identity testing method must include controls to verify the performance of the analysis. A positive control is a protein of known sequence that is analyzed in the same run as the sample. The positive control verifies that the instrument is working correctly and that the digestion is complete.

A negative control is a sample that is not expected to contain the protein. The negative control verifies that the analysis is not contaminated and that the signal is specific to the protein. The negative control is a buffer blank or a sample that is known to be negative.

The controls are analyzed in the same run as the sample. The results of the controls are compared with the expected results. If the controls do not perform as expected, the run is invalid and the sample is reanalyzed.

### Replicates and Reproducibility

The identity testing is performed in replicates to verify the reproducibility of the analysis. The replicates are analyzed in the same run and in different runs. The results of the replicates are compared to verify that the analysis is reproducible.

The reproducibility is assessed by comparing the sequence coverage and the mass accuracy of the replicates. The coverage and the mass accuracy should be consistent between replicates. The variability is documented and is used to set the acceptance criteria.

The reproducibility is a measure of the quality of the analysis. A reproducible analysis is one that produces the same result when the same sample is analyzed multiple times. The reproducibility is affected by the digestion, the chromatography, and the mass spectrometry.

### Acceptance Criteria

The acceptance criteria are the thresholds that the data must meet for the identity test to be considered valid. The criteria are based on the mass accuracy, the sequence coverage, and the quality of the fragment spectra.

The acceptance criteria are defined in the analysis method and are validated before the method is used. The criteria are based on the performance of the instrument and the complexity of the protein. The criteria are documented and are applied consistently to all runs.

The acceptance criteria are used to make a pass or fail decision. If the data meets the criteria, the identity of the protein is confirmed. If the data does not meet the criteria, the identity is not confirmed and the sample is investigated.

## Common Failure Patterns and Troubleshooting

### Incomplete Digestion

Incomplete digestion is a common failure in peptide mapping. The digestion produces peptides that are longer than expected, and the peptide map does not match the predicted pattern. The incomplete digestion is caused by the digestion conditions, such as the temperature, the time, or the ratio of protease to protein.

The troubleshooting of incomplete digestion begins with the digestion conditions. The digestion time is increased, or the temperature is adjusted. The ratio of the protease to the protein is increased. The digestion is repeated with the adjusted conditions.

The incomplete digestion is also caused by the protein structure. A protein that is folded tightly may be resistant to digestion. The protein is denatured more completely before the digestion. The denaturation is achieved by the use of a stronger denaturant or a higher temperature.

### Mass Shift

A mass shift is a difference between the measured mass and the predicted mass. The mass shift is caused by a modification or a sequence variant. The mass shift is the first clue to the nature of the discrepancy.

The mass shift is investigated by comparing the measured mass with the predicted mass. The mass difference is calculated and is compared with the known modifications. The mass shift is localized by peptide mapping.

The mass shift is a common finding in the analysis of proteins that are expressed in a system that introduces modifications. The modifications are identified and are documented in the analysis report.

### Poor Chromatography

Poor chromatography is a failure of the separation. The peptides are not resolved, and the mass spectrometry data is difficult to interpret. The poor chromatography is caused by the column, the mobile phase, or the gradient.

The troubleshooting of poor chromatography begins with the column. The column is replaced or is cleaned. The mobile phase is adjusted, and the gradient is optimized. The chromatography is repeated with the new conditions.

The poor chromatography is identified by the peak shape and the resolution. The peaks are broad or are overlapping. The resolution is the separation of the peaks.

### Low Signal

Low signal is a failure of the detection. The mass spectrometer does not detect the peptides, or the signal is too weak to be interpreted. The low signal is caused by the amount of the protein, the ionization, or the detection.

The troubleshooting of low signal begins with the amount of the protein. The amount of the protein is increased. The ionization is optimized. The detection is adjusted.

The low signal is identified by the signal-to-noise ratio. The signal-to-noise ratio is the ratio of the signal to the background. The signal-to-noise ratio is too low for the interpretation.

## Records and Measurements

### Documentation of the Reference Sequence

The reference sequence is the standard for the identity testing. The sequence is documented in the analysis method. The sequence is stored in a format that can be used by the analysis software.

The documentation includes the source of the sequence, the date of the sequence, and the version of the sequence. The documentation is updated when the sequence is changed. The documentation is reviewed and approved.

### Documentation of the Analysis

The analysis is documented in the analysis log. The log includes the date of the analysis, the instrument, the method, and the results. The log includes the sample identification and the reference sequence.

The log is a record of the analysis. The log is used to trace the analysis and to verify the results. The log is reviewed and approved.

### Documentation of the Results

The results of the identity test are documented in the analysis report. The report includes the sequence coverage, the mass accuracy, and the conclusion. The report includes the data and the interpretation.

The report is the final record of the identity test. The report is reviewed and approved. The report is stored in the quality system.

## Biosafety and Regulatory Context

### Biosafety Considerations

The identity testing involves the handling of proteins and the use of mass spectrometry. The biosafety considerations are the handling of the samples and the disposal of the waste. The samples are handled in a way that prevents contamination and exposure.

The biosafety principles are described in the Biosafety in Microbiological and Biomedical Laboratories. The principles include the risk assessment, the containment, and the institutional oversight. The risk assessment is the evaluation of the hazards of the work. The containment is the use of the appropriate equipment and practices.

The NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules provide the oversight for the work with recombinant nucleic acids. The guidelines apply to the construction of the expression vector and the expression of the protein. The guidelines are followed in the laboratory.

### Regulatory Context

The identity testing is part of the quality system for the biopharmaceutical products. The regulatory context is the requirement for the identity testing in the release of the product. The regulatory context is the requirement for the documentation and the validation of the method.

The regulatory context is the requirement for the quality of the product. The quality is the identity, the purity, the potency, and the safety. The identity is the confirmation that the product is the intended protein.

The regulatory context is the requirement for the validation of the method. The validation is the demonstration that the method is suitable for the intended use. The validation is the documentation of the method.

## Professional Escalation Criteria

The identity testing is a technical analysis that requires the expertise of the analyst. The analyst is responsible for the quality of the data and the interpretation of the results. The analyst is responsible for the escalation of the issues.

The escalation criteria are the conditions that require the involvement of the supervisor or the specialist. The escalation criteria are the unexpected results, the failure of the controls, and the inability to interpret the data.

The escalation is the communication of the issue to the supervisor. The escalation is the documentation of the issue. The escalation is the resolution of the issue.

## Decision Framework for Selecting Identity Testing Depth

### Matching Method Complexity to Product Risk

The choice between intact mass analysis alone, peptide mapping, or a full tandem mass spectrometry workflow depends on the product stage and the consequence of an undetected identity error. A one-size-fits-all approach wastes resources on early research samples while leaving late-stage products undercharacterized. The decision framework below uses product stage, sequence complexity, and regulatory requirement as the three primary inputs.

For early research samples where the protein is used to test a hypothesis, intact mass analysis alone is often sufficient. The cost of an undetected sequence variant is a failed experiment, and the cost of reanalysis is low. For process development samples where the expression system is being optimized, peptide mapping is the appropriate choice because it can detect the sequence variants that arise from cloning errors or expression strain mutations. For release testing of a product intended for clinical use, the full workflow with tandem mass spectrometry is required because the consequence of an identity error is a regulatory rejection or a patient safety event.

The decision framework is documented in the analysis method and is applied consistently. The framework is reviewed when the product moves from one stage to the next. The review is triggered by a change in the product stage, a change in the expression system, or a change in the regulatory requirement.

### Risk-Based Decision Matrix

The decision matrix uses three risk levels. Low risk is a research sample with no regulatory requirement and a simple sequence. Medium risk is a development sample with a known expression system and a moderate sequence complexity. High risk is a release sample with a regulatory requirement and a complex sequence that includes post-translational modifications.

For a low-risk sample, the decision is intact mass analysis only. The mass accuracy is verified against the predicted mass, and the result is recorded. If the mass matches within the acceptance criteria, the identity is confirmed. If the mass does not match, the sample is escalated to peptide mapping.

For a medium-risk sample, the decision is intact mass analysis followed by peptide mapping. The intact mass analysis is the screening step, and the peptide mapping is the confirmation step. The sequence coverage is calculated, and the coverage must meet the acceptance criteria. If the coverage is below the threshold, the digestion is repeated or the sample is escalated.

For a high-risk sample, the decision is the full workflow. The intact mass analysis is performed, the peptide mapping is performed, and the tandem mass spectrometry is performed on the peptides that are not confirmed by the mass alone. The sequence coverage is calculated, and the coverage must meet the acceptance criteria. The fragment spectra are interpreted, and the sequence is confirmed at the residue level.

The decision matrix is a table in the analysis method. The table lists the risk level, the product stage, the required methods, and the acceptance criteria. The table is reviewed and approved by the supervisor.

### Sequence Complexity Assessment

The sequence complexity is a factor in the decision matrix. A protein with a simple sequence, such as a small peptide or a protein with no post-translational modifications, requires less analysis than a protein with a complex sequence, such as a glycoprotein or a protein with multiple disulfide bonds.

The complexity is assessed by the number of amino acids, the number of potential modification sites, and the presence of disulfide bonds. The complexity is documented in the analysis method. The complexity is used to set the acceptance criteria for the sequence coverage.

A protein with a high complexity requires a higher sequence coverage. The coverage is the percentage of the sequence that is confirmed by the observed peptides. A coverage of 90 percent is typical for a simple protein, and a coverage of 95 percent is typical for a complex protein. The coverage is calculated by the analysis software and is reported in the analysis report.

The complexity assessment is a judgment call. The analyst uses the sequence information and the expression system to make the assessment. The assessment is documented and is reviewed by the supervisor.

### Regulatory Requirement Assessment

The regulatory requirement is the third input to the decision matrix. The requirement is the expectation of the regulatory authority for the identity testing of the product. The requirement is determined by the product stage and the intended use.

For a research product, there is no regulatory requirement. The identity testing is performed for the internal quality control. For a development product, the regulatory requirement is the expectation of the regulatory authority for the product to be characterized. For a release product, the regulatory requirement is the expectation of the regulatory authority for the product to be released.

The regulatory requirement is documented in the analysis method. The requirement is the basis for the acceptance criteria. The requirement is reviewed and approved by the quality unit.

The regulatory requirement is a factor in the decision matrix. The requirement is the reason for the full workflow for a release product. The requirement is the reason for the peptide mapping for a development product. The requirement is the reason for the intact mass analysis for a research product.

## Record System for Identity Testing Decisions

### The Decision Log

The decision log is the record of the identity testing decisions. The log includes the sample identification, the product stage, the risk level, the methods used, and the acceptance criteria. The log is a record of the decision and the rationale for the decision.

The decision log is a table. The table lists the sample identification, the date, the product stage, the risk level, the methods used, and the acceptance criteria. The table is filled in by the analyst and is reviewed by the supervisor.

The decision log is a record of the decision. The log is used to trace the decision and to verify the decision. The log is reviewed and approved.

### The Analysis Log

The analysis log is the record of the analysis. The log includes the date of the analysis, the instrument, the method, and the results. The log includes the sample identification and the reference sequence.

The analysis log is a record of the analysis. The log is used to trace the analysis and to verify the results. The log is reviewed and approved.

The analysis log is a table. The table lists the date, the instrument, the method, the sample identification, and the results. The table is filled in by the analyst and is reviewed by the supervisor.

### The Result Report

The result report is the final record of the identity test. The report includes the sequence coverage, the mass accuracy, and the conclusion. The report includes the data and the interpretation.

The result report is a record of the identity test. The report is used to communicate the result to the quality unit and to the regulatory authority. The report is reviewed and approved.

The result report is a table. The table lists the sample identification, the date, the sequence coverage, the mass accuracy, and the conclusion. The table is filled in by the analyst and is reviewed by the supervisor.

### The Decision Record

The decision record is the record of the decision to use a specific method. The record includes the rationale for the decision and the acceptance criteria. The record is a record of the decision and is used to trace the decision.

The decision record is a table. The table lists the sample identification, the product stage, the risk level, the methods used, and the acceptance criteria. The table is filled in by the analyst and is reviewed by the supervisor.

The decision record is the record of the decision. The record is used to trace the decision and to verify the decision. The record is reviewed and approved.

## Troubleshooting the Decision Framework

### When the Intact Mass Does Not Match

The intact mass analysis is the first step in the workflow. The measured mass is compared with the predicted mass. If the mass difference exceeds the acceptance criteria, the sample is escalated to peptide mapping.

The escalation is the decision to perform the peptide mapping. The escalation is documented in the decision log. The escalation is the rationale for the peptide mapping.

The peptide mapping is the localization of the mass difference. The peptide mapping is the confirmation of the sequence. The peptide mapping is the resolution of the mass difference.

### When the Sequence Coverage Is Low

The sequence coverage is the percentage of the sequence that is confirmed by the observed peptides. If the coverage is below the acceptance criteria, the sample is escalated.

The escalation is the decision to repeat the digestion or to use a different protease. The escalation is the decision to perform the tandem mass spectrometry. The escalation is the decision to use a different separation method.

The escalation is documented in the decision log. The escalation is the decision of the analyst. The escalation is the decision of the supervisor.

### When the Controls Fail

The controls are the positive and negative controls. If the controls do not perform as expected, the run is invalid. The run is repeated.

The failure of the controls is the failure of the instrument or the digestion. The failure is the failure of the reagent. The failure is the failure of the method.

The failure is documented in the decision log. The failure is the decision to repeat the run. The failure is the decision to change the reagent.

### When the Result Is Inconclusive

The result is inconclusive when the data does not meet the acceptance criteria. The result is inconclusive when the sequence coverage is low or the mass accuracy is poor. The result is inconclusive when the fragment spectra are not interpretable.

The inconclusive result is the decision to repeat the analysis. The inconclusive result is the decision to change the method. The inconclusive result is the decision to escalate to the supervisor.

The inconclusive result is documented in the decision log. The inconclusive result is the decision of the analyst. The inconclusive result is the decision of the supervisor.

## Practical Implementation Steps

### Step 1: Define the Risk Level

The first step is to define the risk level for the sample. The risk level is determined by the product stage and the sequence complexity. The risk level is documented in the decision log.

The risk level is the input to the decision matrix. The risk level is the basis for the choice of the methods. The risk level is the basis for the acceptance criteria.

### Step 2: Select the Methods

The second step is to select the methods based on the risk level. The methods are the intact mass analysis, the peptide mapping, and the tandem mass spectrometry. The methods are selected from the decision matrix.

The methods are documented in the decision log. The methods are the basis for the analysis. The methods are the basis for the acceptance criteria.

### Step 3: Perform the Analysis

The third step is to perform the analysis. The analysis is the intact mass analysis, the peptide mapping, and the tandem mass spectrometry. The analysis is performed according to the method.

The analysis is documented in the analysis log. The analysis is the basis for the result. The analysis is the basis for the conclusion.

### Step 4: Interpret the Data

The fourth step is to interpret the data. The interpretation is the comparison of the observed data with the predicted data. The interpretation is the calculation of the sequence coverage and the mass accuracy.

The interpretation is documented in the result report. The interpretation is the basis for the conclusion. The interpretation is the basis for the decision.

### Step 5: Document the Decision

The fifth step is to document the decision. The decision is the confirmation of the identity or the escalation of the sample. The decision is documented in the decision log.

The decision is the basis for the release of the product. The decision is the basis for the investigation of the sample. The decision is the basis for the escalation.

## Common Failure Patterns in the Decision Framework

### Overanalysis of Research Samples

The overanalysis of a research sample is a common failure. The research sample is analyzed with the full workflow when the intact mass analysis is sufficient. The overanalysis is a waste of resources and time.

The overanalysis is caused by the lack of a decision framework. The overanalysis is caused by the lack of a risk assessment. The overanalysis is caused by the lack of a decision log.

The overanalysis is prevented by the use of the decision matrix. The overanalysis is prevented by the use of the risk assessment. The overanalysis is prevented by the use of the decision log.

### Underanalysis of a Release Sample

The underanalysis of a release sample is a common failure. The release sample is analyzed with the intact mass analysis only, which is not sufficient for the release. The underanalysis is a risk to the product and the patient.

The underanalysis is caused by the lack of a decision framework. The underanalysis is caused by the lack of a risk assessment. The underanalysis is caused by the lack of a decision log.

The underanalysis is prevented by the use of the decision matrix. The underanalysis is prevented by the use of the risk assessment. The underanalysis is prevented by the use of the decision log.

### Inconsistent Application of the Acceptance Criteria

The inconsistent application of the acceptance criteria is a common failure. The acceptance criteria are applied differently to different samples. The inconsistent application is a risk to the quality of the product.

The inconsistent application is caused by the lack of a documented method. The inconsistent application is caused by the lack of a decision log. The inconsistent application is caused by the lack of a review.

The inconsistent application is prevented by the use of a documented method. The inconsistent application is prevented by the use of a decision log. The inconsistent application is prevented by the use of a review.

### Failure to Document the Decision

The failure to document the decision is a common failure. The decision is not recorded in the decision log. The failure to document is a risk to the traceability of the analysis.

The failure to document is caused by the lack of a decision log. The failure to document is caused by the lack of a review. The failure to document is caused by the lack of a quality system.

The failure to document is prevented by the use of a decision log. The failure to document is prevented by the use of a review. The failure to document is prevented by the use of a quality system.

## Professional Escalation Criteria for the Decision Framework

The escalation criteria for the decision framework are the conditions that require the involvement of the supervisor or the specialist. The escalation criteria are the unexpected results, the failure of the controls, and the inability to interpret the data.

The escalation is the communication of the issue to the supervisor. The escalation is the documentation of the issue. The escalation is the resolution of the issue.

The escalation criteria are documented in the decision log. The escalation criteria are the basis for the decision. The escalation criteria are the basis for the resolution.

The escalation is the decision of the analyst. The escalation is the decision of the supervisor. The escalation is the decision of the quality unit.

## Frequently Asked Questions

### What is the difference between intact mass analysis and peptide mapping?

Intact mass analysis measures the mass of the whole protein and confirms the overall length and composition. Peptide mapping digests the protein into peptides and confirms the sequence at the residue level. Intact mass analysis is a preliminary check, and peptide mapping is the detailed confirmation.

### How is the reference sequence for identity testing established?

The reference sequence is derived from the DNA sequence used to construct the expression vector. The sequence is verified by DNA sequencing of the vector and is documented in the analysis log. The reference sequence is the standard for all mass comparisons.

### What is the role of the digestion in peptide mapping?

The digestion is the step that converts the protein into peptides. The digestion must be complete and reproducible so that the peptide map is consistent. The digestion is optimized for the protein and the protease.

### How is the mass accuracy of the instrument verified?

The mass accuracy is verified by the calibration of the instrument with a standard. The calibration is performed before each run and is documented. The mass accuracy is the difference between the measured and the expected mass.

### What is the sequence coverage and why is it important?

The sequence coverage is the percentage of the protein sequence that is confirmed by the observed peptides. The coverage is important because it shows the extent of the sequence that has been verified. A high coverage is required for a confident identity test.

### What are the common causes of a mass shift?

A mass shift is caused by a modification or a sequence variant. The modification is a change in the mass of the protein. The sequence variant is a change in the amino acid sequence. The mass shift is investigated by the peptide mapping.

### How is the identity test validated?

The identity test is validated by the analysis of the standard and the replicates. The validation is the demonstration that the method is reproducible and accurate. The validation is documented in the analysis method.

### What is the role of the controls in the identity test?

The controls are the samples that are analyzed in the same run as the sample. The positive control verifies the performance of the instrument and the digestion. The negative control verifies the absence of the contamination. The controls are the basis for the validity of the run.

## Using the Evidence

| Source | Best use in this topic | Important limitation |
|---|---|---|
| [Molecular Biology and Laboratory Methods](https://www.ncbi.nlm.nih.gov/books) | official guidance | Check the linked page for current local requirements |
| [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) | official guidance | Check the linked page for current local requirements |
| [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules) | official guidance | Check the linked page for current local requirements |

## Related Molecular Biology Guides

- [Intact Protein Mass Spectrometry: Principles and Applications](/knowledge/molecular-biology/intact-protein-mass-spectrometry)
- [Automated Protein Quantification: Methods and Applications](/knowledge/molecular-biology/automated-protein-quantification)
- [Protein Crystallization: Principles, Methods, and Applications](/knowledge/molecular-biology/protein-crystallization)
- [Protein Quality Assessment: Methods and Applications](/knowledge/molecular-biology/protein-quality-assessment)
- [Protein Quantification Mass Spectrometry: A Practical Guide](/knowledge/molecular-biology/protein-quantification-mass-spectrometry)

## References and Further Reading

- [Molecular Biology and Laboratory Methods](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine.
- [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH.
- [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules). National Institutes of Health.
- [Addgene Protocols](https://www.addgene.org/protocols). Addgene.
- [MIQE Guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762). Clinical Chemistry.
- [NIST Laboratory Programs](https://www.nist.gov/laboratories). National Institute of Standards and Technology.
- [Statistical validation of reproducibility of HPLC peptide mapping for the identity of an investigational drug compound based on principal component analysis.](https://pubmed.ncbi.nlm.nih.gov/11028219). Drug development and industrial pharmacy, 2000.
- [An improved model for prediction of retention times of tryptic peptides in ion pair reversed-phase HPLC: its application to protein peptide mapping by off-line HPLC-MALDI MS.](https://pubmed.ncbi.nlm.nih.gov/15238601). Molecular & cellular proteomics : MCP, 2004.
- [Peptide Mapping for Sequence Confirmation of Therapeutic Proteins and Recombinant Vaccine Antigens by High-Resolution Mass Spectrometry: Software Limitations, Pitfalls, and Lessons Learned.](https://pubmed.ncbi.nlm.nih.gov/41155256). International journal of molecular sciences, 2025.
- [ID-MAM: A Validated Identity and Multi-Attribute Monitoring Method for Commercial Release and Stability Testing of a Bispecific Antibody.](https://pubmed.ncbi.nlm.nih.gov/34161073). Analytical chemistry, 2021.
- [Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring.](https://pubmed.ncbi.nlm.nih.gov/38652517). mAbs, 2024.

> This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.